LINC00599 role in human PASMC proliferation

PRIMARY OUTCOME

PASMC proliferation rates

EXPECTED OUTCOMES

- 1. siRNA knockdown will achieve 70-80% reduction in LINC00599 expression, resulting in 30-40% decrease in PASMC proliferation rates measured by BrdU incorporation - 2. LINC00599 overexpression will increase proliferation by 40-60% compared to empty vector control, with enhanced S-phase entry detected by flow cytometry - 3. Stress granule formation will be significantly impaired in LINC00599 knockdown cells, with 50-70% reduction in G3BP1-positive granules per cell - 4. m6A modification levels on LINC00599 will be detectable by RIP-qPCR, with 3-5 fold enrichment over IgG control - 5. LINC00599 RNA will form liquid droplets with recombinant MYH9 protein in vitro, with droplets showing FRAP recovery times of 10-30 seconds - 6. RNA pulldown will identify MYH9 as a major interacting protein, with 5-10 fold enrichment over control RNA in mass spectrometry analysis - 7. Cell cycle analysis will show LINC00599 promotes G1/S transition, with increased cyclin D1 and CDK4 expression and decreased p21/p27 levels

SUCCESS CRITERIA

- • Achieve >70% knockdown efficiency and >3-fold overexpression confirmed by RT-qPCR with p<0.001 - • Detect statistically significant changes in proliferation (p<0.05) in both loss- and gain-of-function experiments with effect size >20% - • Document stress granule phenotypes with quantitative imaging analysis of >100 cells per condition across 3 independent experiments - • Demonstrate reproducible m6A modification and MYH9 interaction across 3 biological replicates with consistent enrichment ratios - • Phase separation assays must show concentration-dependent droplet formation with >80% reproducibility between technical replicates - • Cell cycle effects must be validated by multiple complementary approaches (flow cytometry, Western blot, gene expression) with consistent directional changes - • All experiments require successful completion in primary PASMCs from at least 3 different donors with comparable results

PROTOCOL

**Phase 1: Cell Culture and Validation** -- Days 1-7 Human PASMCs (Lonza or ScienCell) cultured in SmGM-2 medium with 5% FBS, 1% P/S at 37°C, 5% CO2. Validate cell identity by immunofluorescence staining for smooth muscle markers (α-SMA, SM22α, calponin). Use cells between passages 3-6. Power calculation: n=6 wells per condition for 80% power to detect 20% difference in proliferation with α=0.05. **Phase 2: siRNA Knockdown and Overexpression** -- Days 8-12 Transfect PASMCs at 70% confluency using Lipofectamine RNAiMAX. siRNA conditions: scrambled control (50 nM), LINC00599 siRNA pool (50 nM, 3 sequences). Overexpression: pcDNA3.1-LINC00599 (2 μg/well) or empty vector control using Lipofectamine 3000. Validate knockdown/overexpression at 48h by RT-qPCR using TaqMan probes. **Phase 3: Proliferation and Viability Assays** -- Days 10-15 Proliferation measured by: (1) BrdU incorporation assay (10 μM, 4h pulse) quantified by colorimetric ELISA, (2) Cell counting using hemocytometer at 24, 48, 72h post-transfection, (3) MTT assay for metabolic activity. Cell cycle analysis by propidium iodide staining and flow cytometry. Apoptosis assessment by Annexin V/PI dual staining. **Phase 4: Stress Granule Formation Analysis** -- Days 13-16 Stress granule induction by sodium arsenite (0.5 mM, 30 min) or heat shock (43°C, 45 min). Immunofluorescence staining for stress granule markers: G3BP1 (1:500, Cell Signaling), PABP (1:300, Abcam), and TIA-1 (1:400, Santa Cruz). Quantify stress granule number, size, and colocalization with LINC00599 by FISH using custom probes. Confocal microscopy with 63x objective. **Phase 5: m6A Modification and Phase Separation Studies** -- Days 17-21 RNA immunoprecipitation (RIP) using m6A antibody (Synaptic Systems, 1:100) to assess LINC00599 m6A levels. MeRIP-qPCR validation with specific primers spanning predicted m6A sites. Liquid-liquid phase separation assay: recombinant MYH9 protein (2 μM) mixed with in vitro transcribed LINC00599 RNA (1 μM) in phase separation buffer (50 mM Tris pH 7.5, 150 mM KCl, 10% PEG-8000). Microscopy analysis of droplet formation and FRAP recovery kinetics. **Phase 6: Protein Interaction and Pathway Analysis** -- Days 22-28 RNA pulldown assay using biotinylated LINC00599 followed by mass spectrometry to identify interacting proteins. Validate MYH9 interaction by RNA-IP and Western blot (MYH9 antibody 1:1000, Abcam). Cell cycle gene expression by RT-qPCR array (84 genes). Western blot analysis of key cell cycle proteins: cyclin D1, CDK4, p21, p27 (1:1000 dilutions, overnight 4°C).

HTML iframe

<iframe src="http://scidex.ai/artifact/exp-e61ce538-e572-438b-8a7f-f8677932a3dc?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[LINC00599 role in human PASMC proliferation](http://scidex.ai/artifact/exp-e61ce538-e572-438b-8a7f-f8677932a3dc)

Direct URL

http://scidex.ai/artifact/exp-e61ce538-e572-438b-8a7f-f8677932a3dc

Preview